Dbv Technologies SA 10-Q quarterly reports

DBV Technologies reports progress in VIASKIN Peanut development, with a BLA submission anticipated in Q3 2026, alongside increased operating expenses and a net loss for the period.

DBV Technologies reports Q1 2026 financial results, highlighting a $229.2 million cash position and continued progress toward a BLA submission for Viaskin Peanut.

DBV Technologies reports significant regulatory progress for its Viaskin Peanut patch in both toddler and child age groups, backed by recent financing, despite ongoing operating losses and a going concern warning.

DBV Technologies reported increased net losses and a 'going concern' warning, but secured $125.5 million in new financing and achieved significant regulatory alignment with the FDA for its Viaskin Peanut patch in both toddler and child age groups, potentially accelerating market launch.

DBV Technologies provides a Q1 2025 update, highlighting progress with Viaskin Peanut and a new financing strategy to support its development and potential commercial launch.

DBV Technologies' Q3 2024 report details financial results and provides updates on the regulatory pathway for Viaskin Peanut, including a potential accelerated approval in the US.

DBV Technologies reported its Q2 2024 financial results, highlighting increased R&D spending and a net loss, while also expressing substantial doubt about its ability to continue as a going concern.

DBV Technologies reported a net loss of $27.3 million for the first quarter of 2024, as it continues to advance its Viaskin Peanut clinical program.